A Radical Treatment for Insulin Pricing

A Radical Treatment for Insulin PricingA private, nonprofit company recently announced that it intends to bypass the traditional supply chain and sell interchangeable biosimilar insulin products at substantially reduced prices.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 386; číslo 23; s. 2157 - 2159
Hlavný autor:	Dafny, Leemore S.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 09.06.2022
Predmet:	and the FDA Biological products Brand names Cost control Cost of Health Care Devices Diabetes Drug stores Drugs Endocrinology Generic drugs Health Policy Insulin Patients Pharmaceutical industry Pharmacy Prices Profits Rebates Supply chains United States > US Health Policy Medicine and Business Drug and Device Safety
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!